4SC AG (VSC.F)
- Previous Close
8.88 - Open
7.90 - Bid 7.90 x 165400
- Ask 8.86 x 161000
- Day's Range
7.90 - 8.88 - 52 Week Range
2.96 - 18.10 - Volume
386 - Avg. Volume
648 - Market Cap (intraday)
89.61M - Beta (5Y Monthly) 1.69
- PE Ratio (TTM)
-- - EPS (TTM)
-0.81 - Earnings Date Apr 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.50
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.
www.4sc.comRecent News: VSC.F
Performance Overview: VSC.F
Trailing total returns as of 4/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VSC.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VSC.F
Valuation Measures
Market Cap
89.61M
Enterprise Value
81.29M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
296.38
Price/Book (mrq)
17.74
Enterprise Value/Revenue
267.40
Enterprise Value/EBITDA
-10.71
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.82%
Return on Equity (ttm)
-89.82%
Revenue (ttm)
304k
Net Income Avi to Common (ttm)
-8.24M
Diluted EPS (ttm)
-0.81
Balance Sheet and Cash Flow
Total Cash (mrq)
8.32M
Total Debt/Equity (mrq)
61.40%
Levered Free Cash Flow (ttm)
-6.89M
Research Analysis: VSC.F
Company Insights: VSC.F
VSC.F does not have Company Insights